Nedaplatin

DB13145ApprovedInvestigationalSmall molecule

Nedaplatin is a second generation platinum analog . It is less nephrotoxic than DB00515 but has proven equally effective. It was approved for use in Japan in 1995.

Chemical structure of Nedaplatin
Mechanism
Curator reviewed · 2 references
Primary indication
Used in the treatment of non-small cell lung cancer, small cell lung cancer, oesophygeal cancer, and head and neck cancers.Curator reviewed
Formula / weight
C2H8N2O3Pt · 303.181 g/mol (avg)
Also known as
CDGP
Code names
254-S · CCRIS 4088 · NSC 375101D

Resolves to

Structure
InChIKeyGYAVMUDJCHAASE-UHFFFAOYSA-MSMILES[H][N]([H])([H])[Pt]1(OCC(=O)O1)[N]([H])([H])[H]

What you can answer from here — as of February 21, 2021

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
772Drug interactionsStructured to mechanism, not free text
Sign in
66Clinical trialsPhase, status and sponsor resolved per trial
Sign in
7+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Nedaplatin, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.

Create Account